重组组织型纤溶酶原激活剂联合依达拉奉治疗急性脑梗死疗效观察  

Therapeutic Efficacy of rt-PA Combined with Edaravone on Acute Cerebral Infarction

作　　者：吴景芬[1,2] 常有军[1,3] 吴文斌[1,2] 杨友松[1,2] 陈祥慧[1,2] 

机构地区：[1]四川省医学科学院,四川成都市610072 [2]四川省人民医院神经内科,四川成都市610072 [3]四川省人民医院康复科,四川成都市610072

出　　处：《中国康复理论与实践》2009年第2期158-159,共2页Chinese Journal of Rehabilitation Theory and Practice

摘　　要：目的观察重组组织型纤溶酶原激活剂(rt-PA)及rt-PA联合依达拉奉治疗急性脑梗死的临床疗效及安全性。方法60例符合溶栓条件的急性脑梗死患者分为rt-PA治疗组(予rt-PA治疗)和联合治疗组(予rt-PA联合依达拉奉治疗),各30例,采用欧洲脑卒中临床神经缺损评分标准(ESS)和Barthel指数(BI)评定疗效。结果联合治疗组治疗后21d和90d的ESS积分高于rt-PA治疗组(P<0.05),90d时的疗效优于rt-PA治疗组(P<0.05)。两组患者的不良反应无显著性差异。结论rt-PA联合依达拉奉治疗急性脑梗死更安全有效,能改善患者的预后。Objective To observe the therapeutic efficacy and safety of recombinant tissue-type plasminogen activator （rt-PA） combined with edaravone on acute cerebral infarction （ACI）. Methods 60 cases of ACI were divided into rt-PA group （30 cases, treated by rt-PA only） and trial group （30 cases, treated with rt PA combined with edaravone）. The nerve function deficits of pa tients in both groups were evaluated by European Stroke Scale （ESS） and Barthel Index （BI） before and after treatment respectively. Results The ESS scores at 21st day and 90th day after treatment in the trial group were significantly higher than those of the patients in the rt-PA group. The effective rate of patients in the trial group was significantly higher than those in the rt-PA group （ P 〈0.05）. Conclusion The treatment of rt-PA combined with edaravone is effective and safe in patients with ACI.

关 键 词：重组组织型纤溶酶原激活剂(rt—PA) 依达拉奉 急性脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]